Baidu
map

Amryt 制药公布 III期 EASE试验的疗效分析结果

2019-01-06 MedSci MedSci原创

Amryt是一家孤儿药公司,专注于收购、开发和商业化那些有助于改善高度未满足的医疗需求的产品,Amryt近日宣布AP101作为大疱性表皮松解症(EB)的治疗方法的关键II期EASE试验的非盲临时有效性分析结果。

Amryt是一家孤儿药公司,专注于收购、开发和商业化那些有助于改善高度未满足的医疗需求的产品,Amryt近日宣布AP101作为大疱性表皮松解症(EB)的治疗方法的关键IIEASE试验的非盲临时有效性分析结果。该分析由独立数据监测委员会进行,IDMC建议该试验应继续增加48名患者,共计230名可评估患者,以达到80%的统计效力,Amryt将开始招募所需的额外患者,预计将在2019年下半年从EASE研究中读出最佳数据。

Amryt 首席执行官Joe Wiley表示:“IDMC的建议对于Amryt来说是个好消息,因为它允许我们继续试验,只是适度增加研究规模。这使我们更可能为患者提供治疗EB的有效疗法。我们真诚地感谢参与EASE试验的患者,家属和临床研究人员

AP101Amryt的主要开发资产,其中还包括AP103AP103是一种新型的局部基因疗法,最初是为RDEB(隐性营养不良EB)的治疗而开发的,AP103是基于新的基因治疗递送平台,其使用非病毒递送载体HPAE(高度支化的聚β-氨基酯),该发展计划最近从爱尔兰政府获得了840万欧元的拨款,Amryt预计不久将报告AP103临床前研究结果。


原始出处:

http://www.firstwordpharma.com/node/1615939?tsid=4#axzz5bnF206kJ

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1916063, encodeId=fdbf191606383, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Mon Sep 16 15:58:00 CST 2019, time=2019-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1647226, encodeId=5b24164e22671, content=<a href='/topic/show?id=e9bae04003f' target=_blank style='color:#2F92EE;'>#疗效分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70400, encryptionId=e9bae04003f, topicName=疗效分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=219323401160, createdName=rebeccajiejie, createdTime=Sat Apr 27 20:58:00 CST 2019, time=2019-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594553, encodeId=8d4a159455356, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Jan 08 08:58:00 CST 2019, time=2019-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032032, encodeId=104f103203237, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Sun Jan 06 20:58:00 CST 2019, time=2019-01-06, status=1, ipAttribution=)]
    2019-09-16 juliusluan78
  2. [GetPortalCommentsPageByObjectIdResponse(id=1916063, encodeId=fdbf191606383, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Mon Sep 16 15:58:00 CST 2019, time=2019-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1647226, encodeId=5b24164e22671, content=<a href='/topic/show?id=e9bae04003f' target=_blank style='color:#2F92EE;'>#疗效分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70400, encryptionId=e9bae04003f, topicName=疗效分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=219323401160, createdName=rebeccajiejie, createdTime=Sat Apr 27 20:58:00 CST 2019, time=2019-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594553, encodeId=8d4a159455356, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Jan 08 08:58:00 CST 2019, time=2019-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032032, encodeId=104f103203237, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Sun Jan 06 20:58:00 CST 2019, time=2019-01-06, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1916063, encodeId=fdbf191606383, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Mon Sep 16 15:58:00 CST 2019, time=2019-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1647226, encodeId=5b24164e22671, content=<a href='/topic/show?id=e9bae04003f' target=_blank style='color:#2F92EE;'>#疗效分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70400, encryptionId=e9bae04003f, topicName=疗效分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=219323401160, createdName=rebeccajiejie, createdTime=Sat Apr 27 20:58:00 CST 2019, time=2019-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594553, encodeId=8d4a159455356, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Jan 08 08:58:00 CST 2019, time=2019-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032032, encodeId=104f103203237, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Sun Jan 06 20:58:00 CST 2019, time=2019-01-06, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1916063, encodeId=fdbf191606383, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=40, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Mon Sep 16 15:58:00 CST 2019, time=2019-09-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1647226, encodeId=5b24164e22671, content=<a href='/topic/show?id=e9bae04003f' target=_blank style='color:#2F92EE;'>#疗效分析#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=70400, encryptionId=e9bae04003f, topicName=疗效分析)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=219323401160, createdName=rebeccajiejie, createdTime=Sat Apr 27 20:58:00 CST 2019, time=2019-04-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594553, encodeId=8d4a159455356, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Tue Jan 08 08:58:00 CST 2019, time=2019-01-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1032032, encodeId=104f103203237, content=谢谢梅斯提供这么好的信息,学到很多, beContent=null, objectType=article, channel=null, level=null, likeNumber=55, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=内科新手, createdTime=Sun Jan 06 20:58:00 CST 2019, time=2019-01-06, status=1, ipAttribution=)]
    2019-01-06 内科新手

    谢谢梅斯提供这么好的信息,学到很多

    0

相关资讯

J Invest Dermatol:骨化三醇改善了大疱性表皮松解症小鼠模型的炎症和水泡症状。

近期,维生素D缺乏症和自身免疫性大疱病的发展之间的联系已被提出,但是目前尚没有具体的实验详细阐述过这种联系。本研究探索了维生素D在大疱性表皮松解症(EBA,一种抗Ⅶ型胶原的自身抗体引起的起泡性皮肤疾病)中所扮演的角色。

Constant制药将开展TXA127用于大疱性表皮松解症的临床开发

Constant制药近日宣布,与专注大疱性表皮松解症的慈善机构 - DEBRA(奥地利)、Cure-EB和Epidermolysis Bullosa Research合作开展TXA127的临床开发计划,以治疗罕见的大疱性表皮松解症(EB)。

Baidu
map
Baidu
map
Baidu
map